SCHEMBL6785222

SCHEMBL6785222

CCCCOc1ccc(N(C)C(=O)CC2(O)CCN(C(=O)Cc3ccc4c(c3)OCO4)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
MAPT P10636 4/20 0.47
POLB P06746 2/20 0.47
RAB9A P51151 2/20 0.45
LMNA P02545 5/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP3A4 P08684 2/20 0.43
ABCB11 O95342 1/20 0.43
CYP1A2 P05177 1/20 0.43
ADRA2A P08913 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRM1 P11229 1/20 0.43
TBXA2R P21731 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
CYP2C19 P33261 1/20 0.43
ADRA1A P35348 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785389 0.88 LMNA (0.43) MEN1KMT2AMAPTPOLBRAB9A
SCHEMBL6779964 0.85 SMN1; SMN2 (0.53) MEN1KMT2AMAPTALDH1A1DRD3
SCHEMBL6782805 0.84 HRH2 (0.52) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL6784066 0.80 HTR2A (0.47) ALDH1A1KCNH2
SCHEMBL6784044 0.80 KMT2A (0.51) MEN1KMT2AMAPTPOLBRAB9A
SCHEMBL6783126 0.77 ME2 (0.51) MEN1KMT2AMAPTPOLBRAB9A
SCHEMBL6783675 0.76 ALDH1A1 (0.51) KMT2AMAPTLMNAKDM4EALDH1A1
SCHEMBL6785039 0.75 GPR119 (0.46) KDM4EALDH1A1TDP1
SCHEMBL6786330 0.74 PTPN1 (0.40) KMT2AMAPTPOLBALDH1A1OPRM1
SCHEMBL6897762 0.74 HRH2 (0.42) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6710060-B2 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-03-23 US disclosed
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-12-12 US disclosed
EP-1182192-A1 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity SCN5A, RYR2, SCN1B MEN1 4123/4885KMT2A 2156/4885MAPT 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.